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Background
Systemic sclerosis (SSc) is an autoimmune disease char-
acterized by fibrosis of the skin and the internal organs.
The etiology is still unknown but prominent features are
vascular injury and chronic inflammation resulting in
fibrosis. There are no markers available that predict SSc
susceptibility and/or prognosis. This study is the first
study that exploits a proteome-wide profiling to identify
new targets in the pathogenesis of SSc.
Method
40 SSc patients were included for initial proteomic iden-
tification. Patients were stratified as having diffuse SSc
(dSSc) (n= 19) or limited SSc (lSSc) (n=21) according to
the extent of skin involvement. As controls 20 healthy
donors were included. First we run a training set on the
SELDI-TOF-MS and next the validation set was mea-
sured. For replication a cohort compromising 30 difSSc
patients and 60 limSSc was available.
Results
Analysis revealed a list of 29 masspeaks of interest of
which 21 could be predicted using Tagident. One of the
main significant peaks was S100A8. We next aimed to
replicate the increased expression of S100A8. Further
stratification for SSc disease phenotype reveals it to be
increased solely in limSSc patients with lung fibrosis.
This finding is replicated with an ELISA in 60 limSSc
patients S100A8/A9 being 415 pg/ml in limSSc without
lung fibrosis and 659 pg/ml in limSSc with lung fibrosis
(p<0.05). Furthermore we show an increased presence of
S100A8 in SSc skin sections.
Conclusion
This is the first study identifying new targets in SSc using
proteome wide profiling in serum. S100A8 revealed to be
increased in limSSc patients with lung fibrosis specifi-
cally. As S100A8 is an important protein in inflammatory
processes it is interesting to further investigate its contri-
bution to the pathogenesis of SSc and more specifically
lung fibrosis.
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